Log in

AIT Therapeutics Stock Price, News & Analysis (OTCMKTS:AITB)

Today's Range N/A
50-Day Range
$4.87
MA: $5.08
$5.25
52-Week Range N/A
Volume16,672 shs
Average Volume19,539 shs
Market Capitalization$53.75 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.31
AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AITB
CUSIPN/A
CIKN/A
Phone972-8684-3313

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-18,040,000.00

Miscellaneous

Employees10
Market Cap$53.75 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AITB News and Ratings via Email

Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter.


AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions

What is AIT Therapeutics' stock symbol?

AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."

Has AIT Therapeutics been receiving favorable news coverage?

News stories about AITB stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of -3.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for AIT Therapeutics.

Who are some of AIT Therapeutics' key competitors?

What other stocks do shareholders of AIT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIT Therapeutics investors own include Allena Pharmaceuticals (ALNA), Harvard Bioscience (HBIO), MediciNova (MNOV), Obseva (OBSV), Pieris Pharmaceuticals (PIRS), Matinas BioPharma (MTNB), NovaBay Pharmaceuticals (NBY), Apellis Pharmaceuticals (APLS), Arotech (ARTX) and Athersys (ATHX).

Who are AIT Therapeutics' key executives?

AIT Therapeutics' management team includes the folowing people:
  • Mr. Steven Adam Lisi, CEO & Chairman (Age 48)
  • Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)
  • Mr. Douglas J. Beck, Chief Financial Officer (Age 58)
  • Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
  • Dr. Giora Davidai M.D., Chief Medical Officer

How do I buy shares of AIT Therapeutics?

Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is AIT Therapeutics?

AIT Therapeutics has a market capitalization of $0.00. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 10 workers across the globe.View Additional Information About AIT Therapeutics.

What is AIT Therapeutics' official website?

The official website for AIT Therapeutics is http://www.ait-therapeutics.com/.

How can I contact AIT Therapeutics?

AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.


MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel